Private equity firm JLL Partners makes moves on CROs
This article was originally published in Scrip
Executive Summary
The US private equity company JLL Partners has signed a definitive agreement to acquire the CRO PharmaNet, just a couple of months after saying that it intended to make an unsolicited bid for restricted voting shares of the CRO and manufacturer, Patheon.